The case for & against
Bull & Bear analysis
Bullish
Inventiva S.A. (NASDAQ: IVA) is a French clinical-stage biopharmaceutical company dedicated to developing innovative therapies for metabolic diseases, focusing principally on its leading candidate, lanifibranor. This potential treatment is currently in pivotal Phase 3 trials aimed at addressing metabolic dysfunction-associated steatohepatitis (MASH). Positioned within the therapeutic landscape of metabolic diseases, Inventiva is leveraging strategic partnerships, such as with SinoBioPharm, to enhance its market penetration in significant emerging markets like China while addressing considerable unmet medical needs in areas such as NASH.
Bull says
- ↑FY23 revenue €17.5M (+43% YoY) driven by milestone payments
- ↑Native 3 Phase 3 top-line readout expected Q4 2026
- ↑SinoBioPharm partnership offers China access and €290M milestones
- ↑€233.9M cash runway funds pivotal trials through Q1 2027
- ↑Lani’s direct insulin sensitizer profile may boost physician uptake
- ↑High earnings yield, strong balance sheet and upward earnings revisions
Bear says
- ↓FY23 net loss widened to €110.4M on heavy R&D
- ↓R&D spending up 82% to €110M intensifies cash burn
- ↓High screening failure rates slow enrollment, risking timelines
- ↓Competitive pressure from Madrigal, Intercept and Gilead in NASH
- ↓Weak profitability and earnings yield suggest return challenges
- ↓Elevated volatility and short interest may pressure share price
Earnings Call · Q2 2022 · Mgmt. Guidance
Updated 09-10-2026bullish
Transcript signals
Bull points
- We see Dipartida really as a potential game changer, as being the first oral therapy with the ability to broadly address a wide range of clinical manifestations in MPS6 patients. This market, as you know, is close to a $400 million market.
- The feedback from FDA was that the single phase 2-3 study of one-year duration in MPS-6 patients 5 to 15 years of age could support a fight. This pivotal study that we call POSIGY would be double-blind, randomized, placebo-controlled, evaluating the ability of one dose of adipacil administered in combination with ERT versus placebo in combination with ERT to enhance mobility is the primary objective, and to improve endurance while reducing fatigue and pain.
- we have significant R&D capabilities with over 68 innovative assets in the pipeline, and seven of those are focused on liver diseases.
Bear points
- As I said, no revenues for this semester.
- The screen failure rate is high, and we've seen that, first of all, happening across the entire field of NASH clinical studies.
- The screen failure rate is high, and we've seen that, first of all, happening across the entire field of NASH clinical studies.
Read full transcript analysis ›